Olanzapine
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
- Olanzapine
- Olanzapine: From Schizophrenia/Bipolar Disorder to Agoraphobia (Treatment-Resistant Panic Disorder)
Olanzapine: From Schizophrenia/Bipolar Disorder to Agoraphobia (Treatment-Resistant Panic Disorder)
One-Sentence Summary
Olanzapine is a well-established atypical antipsychotic used for schizophrenia and bipolar I disorder. Among three TxGNN-predicted new indications in this evidence pack, the most clinically credible signal points to Agoraphobia, specifically as an augmentation therapy in treatment-resistant panic disorder, supported by 7 publications (no dedicated clinical trials yet). Evidence level is L3, and a critical safety data gap (TFDA warnings/contraindications) currently blocks full risk assessment.
Note: This evidence pack contains 3 TxGNN-predicted indications for olanzapine. The top TxGNN-ranked prediction ("benign paroxysmal torticollis of infancy") is explicitly flagged in its own rationale as having no mechanistic support and a serious pediatric safety concern, so it is not used as the lead indication in this report. See "Other Predicted Indications" below.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the evidence pack. (General pharmacology background: olanzapine is an atypical antipsychotic typically approved for schizophrenia and bipolar I disorder — not sourced from this evidence pack.) |
| Predicted New Indication | Agoraphobia (as augmentation in treatment-resistant panic disorder) |
| TxGNN Prediction Score | 99.47% (rank 5685) |
| Evidence Level | L3 |
| Market Status | ✗ Not marketed (0 authorizations on record) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed formal MOA data for olanzapine (original_moa) is flagged as a data gap in this evidence pack (DG002). Based on the mechanistic rationale extracted from the literature evidence itself, olanzapine acts as a D2/5-HT2A receptor antagonist. This dual dopaminergic-serotonergic modulation is theorized to reduce anxiety and catastrophic cognitive interpretation in patients with treatment-resistant panic disorder and agoraphobia.
Critically, the literature does not support olanzapine as monotherapy for agoraphobia. Rather, the strongest study (Sepede et al., 2006, 12-week open-label fixed-dose trial) evaluated low-dose olanzapine (5 mg/d) as an add-on to SSRIs in patients who had already failed SSRI monotherapy. This is consistent with the broader literature theme: olanzapine augmentation in SSRI/SNRI-resistant panic disorder with agoraphobia, not first-line or standalone treatment.
Because the original approved use (schizophrenia/bipolar disorder) and the predicted new use (anxiety/panic-spectrum disorder) both involve modulation of dopaminergic-serotonergic circuitry implicated in mood and anxiety regulation, the mechanistic extension to a treatment-resistant anxiety indication is biologically plausible, though it remains supported only by small open-label and case-level evidence rather than confirmatory RCTs.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16415705 | 2006 | Open-label trial (12-week, fixed-dose) | Journal of Clinical Psychopharmacology | Low-dose olanzapine (5 mg/d) added to SSRI in 31 SSRI-resistant panic disorder patients (with/without agoraphobia); assessed via Panic Attack and Anticipatory Anxiety Scale |
| 40946318 | 2025 | Integrative Systematic Review | Psychotherapy and Psychosomatics | Reviews pharmacological, psychotherapeutic, and neurostimulatory options for treatment-resistant anxiety disorders |
| 26635099 | 2016 | Systematic Review | Expert Opinion on Pharmacotherapy | Reviews treatment options for treatment-resistant panic disorder, a population with persistent symptoms despite standard therapy |
| 25012437 | 2014 | Cohort (24-month naturalistic outcome) | Journal of Affective Disorders | Comorbid agoraphobia/panic/OCD/GAD worsen 24-month clinical outcomes in bipolar I disorder |
| 10739446 | 2000 | Case Report | The American Journal of Psychiatry | Early case report describing olanzapine's effect on panic attacks |
| 15470803 | 2004 | Case Report | Pharmacopsychiatry | Chronic, treatment-refractory panic disorder patient remitted on olanzapine + paroxetine combination |
| 17099612 | 2006 | Case Report (CBT case series) | Psychiatria Danubina | Case of comorbid panic disorder with agoraphobia and psychosis, successfully treated with CBT; olanzapine context discussed |
Norway Market Information
Not currently marketed. The evidence pack lists 0 authorizations, so no license table is available.
Safety Considerations
Please refer to the package insert for safety information.
⚠ Blocking Data Gap (DG001): TFDA-equivalent label warnings and contraindications for olanzapine are not available in this evidence pack. This is flagged as a Blocking severity gap — it prevents this candidate from progressing to the S1 safety review stage. No drug-drug interaction data was found (
query_status: not_found).
Other Predicted Indications (Lower Priority)
| Rank | Indication | TxGNN Score | Evidence Level | Recommendation | Note |
|---|---|---|---|---|---|
| 1 | Benign paroxysmal torticollis of infancy | 99.54% | L5 | Hold | No mechanistic link identified; this is a pediatric migraine-spectrum condition with no pathophysiological connection to D2/5-HT2A antagonism. Using an antipsychotic in infants raises serious safety concerns. TxGNN score reflects graph-based association only, not clinical plausibility. |
| 3 | Dysthymic disorder | 99.28% | L4 | Hold | Evidence is indirect — one open-label trial in comorbid borderline personality disorder + dysthymia, plus class-level (second-generation antipsychotic) reviews for MDD/dysthymia, and unrelated-drug (amisulpride, substituted benzamides) evidence. No olanzapine-specific controlled trial for dysthymia exists. |
Conclusion and Next Steps
Decision: Hold
Rationale: The agoraphobia signal has the most credible mechanistic and literature support among the three predicted indications (D2/5-HT2A augmentation therapy in SSRI-resistant panic disorder/agoraphobia), but it rests on evidence level L3 with no controlled trials — only one 12-week open-label study and several case reports/reviews. More importantly, the blocking data gap on TFDA safety information (DG001) means this candidate cannot yet pass initial safety screening (S1), regardless of the promising efficacy signal.
To proceed, the following is needed:
- Resolve DG001: obtain TFDA-equivalent label (warnings, contraindications) via official regulatory source
- Resolve DG002: obtain formal MOA/pharmacology data via DrugBank API
- Identify or commission a controlled trial (RCT) specifically evaluating olanzapine augmentation in treatment-resistant agoraphobia/panic disorder
- If pursuing lower-ranked predictions (dysthymic disorder, torticollis), first establish a credible mechanistic rationale and pediatric-specific safety data before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.